Modality
ASO
MOA
BTKi
Target
WRN
Pathway
RAS/MAPK
MCC
Development Pipeline
Preclinical
Apr 2020
→ Feb 2025
PreclinicalCurrent
NCT05465371
262 pts·MCC
2020-04→TBD·Not yet recruiting
NCT07119774
1,502 pts·MCC
2021-12→2025-02·Completed
1,764 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-141.1y agoInterim· MCC
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
Preclinical
Not yet…
Preclinical
Complet…
Catalysts
Interim
2025-02-14 · 1.1y ago
MCC
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05465371 | Preclinical | MCC | Not yet recr... | 262 | PANSS |
| NCT07119774 | Preclinical | MCC | Completed | 1502 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 |